Idiopathic pulmonary fibrosis: The need for early diagnosis

Multidisciplinary Respiratory Medicine

Volumn 8, Issue 8, 2013, Pages

  Cicchitto, Gaetano ^a   Sanguinetti, Claudio M ^b  

^a ASL SA/3   (Italy)

^b Multidisciplinary Respiratory Medicine   (Italy)

Author keywords

Biomarkers; Early diagnosis; Idiopathic pulmonary fibrosis; Omics

Indexed keywords

CALGRANULIN B; CHITINASE; GLYCOPROTEIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; EARLY DIAGNOSIS; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; LUNG LAVAGE; PROGNOSIS; RADIOLOGICAL PARAMETERS;

EID: 84884885493     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-8-53     Document Type: Article

References (66)

1. Raghu G: An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011, 66:462-467.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2006, 174:810-816. (Pubitemid 44511663)
4. Frankel SK, Schwarz MI: Update in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2009, 15:463-469.
5. Vancheri C, Failla M, Crimi N, Raghu G: Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010, 35:496-504.
6. King TE Jr, Pardo A, Selman M: Idiopathic Pulmonary Fibrosis. Lancet 2011, 378:1949-1961.
7. Richeldi L: Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012, 21:147-151.
8. Cottin V: Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcome. Eur Respir Rev 2012, 21:161-167.
9. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, Du Bois R, CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
10. Papiris SA, Kagouridis K, Kolilekas L, Triantafillidou C, Tsangaris I, Manali ED: Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Eur Respir J, 2012, 40:794-795.
11. Albera C: Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011, 20:195-200.
12. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KL, Schwartz DA, Noble PW, Raghu G, Brown KK, For the IPF Study Group: The clinical course of patients with Idiopathic Pulmonary Fibrosis. Ann Intern Med 2005, 142:963-967.
13. Kim DS, Collard HR, King TE Jr: Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3:285-292. (Pubitemid 43845404)
14. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF, The Grouped'Etude et de Recherchesur les Maladies Orpheline" Pulmonaires (GERM"O"P): Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26:586-593.
15. Nashimura K, Kitaichi M, Izumi T, Nagai S, Kanaoka M, Itoh H: Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992, 182:337-342.
16. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG: Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010, 11:89.
17. Vij R, Noth I: Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012, 159:218-227.
18. Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012, 18:441-446.
19. Kaas DJ, Kaminski N: Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes. Clin Transl Sci 2011, 4:372-379.
20. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A: Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006, 173:188-198. (Pubitemid 43187891)
21. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE Jr, Pardo A, Kaminski N: Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007, 5:482.
22. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA: Molecular phenotypes distinguish patients with relatively stable from progressive Idiopathic Pulmonary Fibrosis (IPF). PLoS One 2009, 4:5134.
23. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglie M, Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N: Gene expression profiles of acute exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2009, 180:167-175.
24. Ecclestone A, De Witt N, Gunter C, Marte B, Nath D: Epigenetics. Nature 2007, 447:395. (Pubitemid 46816730)
25. Sanders YY, Hagood JS: The effects of histon deacetylase inhibitors on fibrotic lung fibroblasts survival and apoptosis. Am J Respir Crit Care Med 2010, 181:A2015.
26. Yang IV, Schwartz DA: Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011, 183:1295-1301.
27. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, Bray M, Zhang K, Thannickal VJ, Hagood JS: Altered DNA methylation profile in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012, 186:525-535.
28. Pandit KV, Milosevic J, Kaminski N: MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011, 157:191-199.
29. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E: miR-21mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010, 207:1589-1597.
30. Pottier N, Maurin T, Chevalier B, Puisségur MP, Lebrigand K, Robbe-Sermesant K, Bertero T, Cardenas CLL, Courcot E, Rios G, Fourre S, Lo Guidice JM, Marcet B, Cardinaud B, Barbry P, Mari B: Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One 2009, 4:e6718.
31. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M, Watkins SC, Pardo A, Ben-Yehudah A, Bouros D, Eickelberg O, Ray P, Benos PV, Kaminski N: Inhibition and role of let-7d in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2010, 182:220-229.
32. Yang IV: Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012, 4:195-203.
33. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright VP, Nana-Sinkam SP, Piper MG, Marsh CB: Epigenetic regulation of miR-17 92 contributes to the pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med 2013, 187:397-405.
34. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazeroony EA, Gross BH, Jain A, Strawdermann RL III, Flint A, Lynch JP III, Martinez FJ: Histopathologic variability in usual and nonspecific Interstitial Pneumonias. Am J Respir Crit Care Med 2001, 164:1722-1727. (Pubitemid 33124165)
35. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001, 17:175-179. (Pubitemid 32600574)
36. Prasse A, Muller-Quernheim J: Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009, 14:788-795.
37. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, MacDonald SD, Pardo A, Sciurba F, Dauber J, Seman M, Gochuico BR, Kaminski N: MMP1 and MMP7 as potential peripheral blood biomarkers in Idiopathic Pulmonary Fibrosis. PLoS Med 2008, 5:93.
38. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ: Serum surfactants proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446. (Pubitemid 34256957)
39. Kinder BW, Brown KK, Mc Cormack FX, Ix JH, Kervitski A, Schwarz MI, King TE Jr: Serum surfactant protein-A is a strong predictor of early mortality in Idiopathic Pulmonary Fibrosis. Chest 2009, 135:1557-1563.
40. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N: KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005, 338:1845-1852. (Pubitemid 41643100)
41. Hirasawa Y, Kohno N, Yokohama A, Inoue Y, Abe M, Hiwada K: KL6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997, 17:501-507. (Pubitemid 127500983)
42. Kobayas J, Kitamura S: KL-6: A serum marker for Interstitial Pneumonia. Chest 1995, 108:311-315.
43. Ohnishi H, Yokoama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N: Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for Interstitial Lung Diseases. Am J Respir Crit Care Med 2002, 165:378-381. (Pubitemid 34118512)
44. Kinoshita K, Hamano H, Harado H, Kinoshita T, Igishi T, Hagino H, Ogawa T: Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004, 98:1131-1137. (Pubitemid 39317944)
45. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M: Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006, 260:429-434. (Pubitemid 44571130)
46. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686. (Pubitemid 39457982)
47. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldman T, Vollmer E, Muller-Quernheim J, Zissel G: A vicious circle of alveolar macrophages and fibroblasts perpetuates Pulmonary Fibrosis via CCL8. Am J Respir Crit Care Med 2006, 173:781-792.
48. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschevski M, Rottoli P, Müller-Quernheim J: Serum CC-chemokine ligand 18 concentration predicts outcome in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2009, 179:717-723.
49. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M: Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999, 14:376-382. (Pubitemid 29461305)
50. Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H, Kusagaya H, Nakano Y, Nakamura H, Chida K: Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 2010, 104:1204-1210.
51. Korthagen NM, Van Moorsel CHM, Barlo NP, Ruven HJT, Kruit A, Heron M, van den Bosch JMM, Grutters JC: Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011, 105:106-113.
52. Hara A, Sakamoto N, Ishimatsu Y, Kakugawa T, Nakashima S, Hara S, Adachi M, Fujita H, Mukae H, Kohno S: S100A9 in BALF is a candidate biomarker of pulmonary fibrosis. Respir Med 2012, 106:571-580.
53. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF: Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012, 185:67-76.
54. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M: Circulating Fibrocyte Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2009, 179:588-594.
55. Nukiwa T: Interstitial Lung Disease. In The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. 46th edistion. Edited by Du Bois RM, Richeldi L. ERS Monograph; 2009:47-66.
56. Rottoli P, Bargagli E, Landi C, Magi B: Proteomic analysis in interstitial lung diseases: a review. Curr Opin Pulm Med 2009, 15:470-478.
57. Yang IV, Luna LG, Cotter J, Talbert J, Leach SM, Kidd R, Turner J, Kummer N, Kervitsky D, Brown KK, Boon K, Schwarz MI, Schwartz DA, Steele MP: The Peripheral Blood Transcriptome Identifies the Presence and Extent of Disease in Idiopathic Pulmonary Fibrosis. PLoS One 2012, 7:37708.
58. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, Cianti R, Bini L, Pallini V: Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005, 5:1423-1430.
59. Studer SM, Kaminski N: Towards systems biology of human Pulmonary Fibrosis. Proc Am Thorac Soc 2007, 4:85-91. (Pubitemid 46084774)
60. Center DM, Schwartz DA, Solway J, Gail D, Laposki AD, Lin QS, Gan W: Genomic medicine and lung diseases. Am J Respir Crit Care Med 2012, 186:280-285.
61. Lee JS, McLaughlin S, Collard HR: Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011, 17:348-354.
62. Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, Schwarz MI, Schwartz DA: Gene expression profiling of familial and sporadic Interstitial Pneumonia. Am J Respir Crit Care Med 2007, 175:45-54. (Pubitemid 46105308)
63. Danil ZD, Papageorgiou E, Koutsokera A, Kostikas K, Kiropoulos T, Papaioannou AI, Gourgoulianis KI: Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2008, 21:26-31.
64. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK: Telomere shortening in familial and sporadic Pulmonary Fibrosis. Am J Respir Crit Care Med 2008, 178:729-737.
65. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, Du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CM, Schwarz MI, Schwartz DA: A common MUC5B promoter polymorphism and Pulmonary Fibrosis. N Eng J Med 2011, 364:1503-1512.
66. Lung Genomics Research Consortium: www. lung-genomics. org.